Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 6/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.43 |
| ▸ | ELANE | P08246 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | GSR | P00390 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.40 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29808797 | 0.91 | NOTUM (0.76) | NOTUMALDH1A1POLBCYP1A2ALKBH5 | |
| SCHEMBL5752612 | 0.91 | NOTUM (0.76) | NOTUMALDH1A1POLBCYP1A2ALKBH5 | |
| SCHEMBL4021797 | 0.86 | NOTUM (0.49) | NOTUMALDH1A1CYP1A2ELANELMNA | |
| SCHEMBL4021451 | 0.85 | ELANE (0.56) | NOTUMALDH1A1POLBELANELMNA | |
| SCHEMBL31028430 | 0.84 | MEN1 (0.54) | NOTUMALDH1A1POLBCYP1A2LMNA | |
| SCHEMBL4023334 | 0.84 | MEN1 (0.54) | NOTUMALDH1A1POLBCYP1A2LMNA | |
| SCHEMBL11895153 | 0.84 | NOTUM (0.47) | NOTUMALDH1A1CYP1A2ELANELMNA | |
| SCHEMBL8065166 | 0.83 | NOTUM (0.65) | NOTUMPOLBCYP1A2ALKBH5ELANE | |
| SCHEMBL11895074 | 0.83 | CNR2 (0.53) | NOTUMALDH1A1POLBELANELMNA | |
| SCHEMBL11894963 | 0.83 | CNR1 (0.51) | NOTUMALDH1A1ELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1663974-B1 | 2-PYRIDONE DERIVATIVES AS NETROPHIL ELASTASE INHIBITORS AND THEIR USE | ASTRAZENECA AB (SE) | 2009-01-14 | — | — | EP | disclosed |
| CN-100439339-C | 2-pyridone derivatives as netrophil elastase inhibitors and their use. | ASTRAZENECA AB (SE) | 2008-12-03 | — | — | CN | disclosed |
| US-20070043036-A1 | 2-Pyridone derivatives as neutrophil elastase inhibitors and their use | ASTRAZENECA AB (SE) | 2007-02-22 | — | — | US | disclosed |
| CN-1856467-A | 2-pyridone derivatives as inhibitors of neutrophil elastase and uses thereof | ASTRAZENECA AB (SE) | 2006-11-01 | — | — | CN | disclosed |
| EP-1663974-A1 | 2-PYRIDONE DERIVATIVES AS NETROPHIL ELASTASE INHIBITORS AND THEIR USE | AstraZeneca AB (SE) | 2006-06-07 | — | — | EP | disclosed |
| WO-2005026124-A1 | 2-PYRIDONE DERIVATIVES AS NETROPHIL ELASTASE INHIBITORS AND THEIR USE | ASTRAZENECA AB (SE) | 2005-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043036-A1 | 2-Pyridone derivatives as neutrophil elastase inhibitors and their use | SERPINB1, ELANE, SERPINE1 | NOTUM 3343/4885ALDH1A1 1362/4885POLB 622/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.